MDT Medtronic plc

MDT financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1613103 Exchange: NYSE SIC: 3845 (Electromedical & Electrotherapeutic Apparatus) Latest filing: 10-Q filed Sep 3, 2026 Data checked: Oct 21, 2026
Showing 3 of 14 annual and 0 of 49 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Large accelerated filer
Entity Type
Operating
Public Float
$120.10B (Oct 2025)
Industry (SIC)
3845 Electromedical & Electrotherapeutic Apparatus
Fiscal Year End
April (0424)
Phone
01135314381700
EIN
000000000
Headquarters
GALWAY, H91 4K49
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: Medtronic Ltd (2015–2015) · Medtronic Holdings Ltd (2014–2014)

▼ Key Metrics (TTM)

As of Jul 31, 2026
Financials
Revenue
$37.54B
Net Income
$5.23B
Total Assets
$93.31B
Total Equity
$50.85B
Total Debt
-
Free Cash Flow
$6.13B
Ratios
Gross Margin
65%
Operating Margin
18.1%
Net Margin
13.9%
Return on Equity
10.3%
Return on Assets
5.6%
Current Ratio
2.07x
FCF / Assets
6.6%

▼ FY 2026 Summary Analysis

Annual report ending Apr 24, 2026

Overview and Growth

Medtronic plc generated $36.36B of revenue in fiscal 2026, with net income of $4.80B and an operating cash inflow of $7.33B. Revenue of $36.36B sets the scale for evaluating how effectively sales translated into profit and cash during the year. Compared with $33.54B in fiscal 2025, revenue recorded a 8.4% year-over-year increase. The company reported diluted EPS of $3.73, adding a shareholder-level measure to the absolute income figures considered below. Diluted EPS increased by 3.3% from $3.61 in fiscal 2025, showing how the earnings change reached shareholders on a per-share basis. Asset turnover was 0.39x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

The first profit layer was $23.64B of gross profit, the amount available after reported direct revenue costs to absorb operating expenses. Gross margin was 65.0%, so that share of each revenue unit remained after the cost of revenue reported for the period. The reported operating result was $6.47B, capturing profitability after direct costs and the operating expenses reflected in the statements. Relative to revenue, operating income represented 17.8%, showing how efficiently sales converted into operating profit. The bottom-line result was net income of $4.80B, after the operating, financing, tax, and other items recognized for the period. The final earnings result represented 13.2% of revenue, connecting the absolute net income figure with the company’s top-line scale. The earnings statement records $6.14B of pretax income, the profit base against which the reported tax provision can be assessed. Pretax income represented 16.9% of revenue, placing earnings before tax in the context of the company’s operating scale. Income tax expense totaled $1.30B, providing the reported tax component that separates pretax and after-tax earnings. The effective relationship between income tax and positive pretax income was 21.2%, without assuming a statutory-rate comparison. The relationship between net income and period-end equity was 9.6%, indicating the profitability achieved on book capital. The net-income-to-assets relationship measured 5.2%, showing earnings relative to the full balance sheet.

Liquidity and Capital Structure

At period end, the $93.03B asset base was financed through $42.96B of liabilities and $50.07B of equity. Current assets were $24.79B against $11.66B of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. Current assets covered current liabilities by 2.13x, leaving a positive buffer for near-term obligations. Cash and equivalents totaled $1.95B, identifying the most liquid reported component available within the broader current-asset balance. Cash and equivalents represented 16.7% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Relative to total assets, liabilities measured 46.2%, complementing the separate equity-based view of the company’s capital structure. Cash and equivalents equaled 2.1% of total assets, showing the liquid cash component within the company’s broader resource base. Total assets were 1.5% higher than fiscal 2025 assets of $91.68B, measuring the company’s own balance-sheet change.

Cash Flow and Earnings Quality

Cash flow from operations was $7.33B, a reported cash inflow that can be compared directly with net income and capital spending. Against net income, operating cash flow measured 1.53x, showing the relationship between accrual earnings and operating cash. The cash-flow statement records $1.90B of capital expenditures, the investment amount considered after operating cash generation. Relative to operating cash flow, capital expenditures measured 26.0%, connecting investment intensity with the company’s cash-generation base. Free cash flow came to $5.43B, leaving a positive amount after capital expenditures. The free-cash-flow margin was 14.9%, measuring cash remaining after capital spending against revenue. Free cash flow equaled 5.8% of total assets, relating post-investment cash generation to the company’s resource base.
Based on the annual report for the fiscal year ending Apr 24, 2026. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Medtronic plc
Metric FY2026 📄 FY2025 📄 FY2024 📄
Income Statement
REVENUE
Revenue $36.36B $33.54B $32.36B
Cost of Revenue $12.72B $11.63B $11.22B
Gross Profit $23.64B $21.91B $21.15B
OPERATING EXPENSES
R&D Expense $2.87B $2.73B $2.74B
SG&A Expense $11.78B $10.85B $10.74B
Other Operating Expenses (derived) $2.52B $2.37B $2.53B
Operating Income $6.47B $5.96B $5.14B
NON-OPERATING INCOME / EXPENSE
Interest Expense - - $719.00M
Other Income/Expense $384.00M $402.00M $412.00M
Pretax Income $6.14B $5.63B $4.84B
Income Tax $1.30B $936.00M $1.13B
Net Income $4.80B $4.66B $3.68B
PER SHARE & SUPPLEMENTAL
Diluted EPS $3.73 $3.61 $2.76
Diluted Shares 1.29B 1.29B 1.33B
EBITDA $9.43B $8.82B $7.79B
Depreciation & Amortization $2.96B $2.86B $2.65B
Balance Sheet
ASSETS
Cash & Equivalents $1.95B $2.22B $1.28B
Short-term Investments $7.27B $6.75B $6.72B
Accounts Receivable $6.64B $6.52B $6.13B
Inventory $5.95B $5.48B $5.22B
Other Current Assets $2.97B $2.86B $2.58B
Current Assets $24.79B $23.81B $21.94B
PP&E (Net) $7.42B $6.84B $6.13B
Goodwill $42.59B $41.74B $40.99B
Intangible Assets $10.15B $11.67B $13.23B
Other Noncurrent Assets $4.15B $3.58B $4.05B
Noncurrent Assets $68.24B $67.87B $68.05B
Total Assets $93.03B $91.68B $89.98B
LIABILITIES
Accounts Payable $2.64B $2.45B $2.41B
Short-term Debt $1.79B $2.87B $1.09B
Other Current Liabilities $3.63B $3.68B $3.58B
Current Liabilities $11.66B $12.88B $10.79B
Other Noncurrent Liabilities $2.06B $1.77B $1.37B
Noncurrent Liabilities $31.30B $30.55B $28.77B
Total Liabilities $42.96B $43.42B $39.56B
EQUITY
Common Stock $0 $0 $0
Additional Paid-in Capital $20.93B $20.83B $23.13B
Retained Earnings $32.64B $31.48B $30.40B
Accumulated OCI $-4.10B $-4.28B $-3.32B
Total Equity $50.07B $48.26B $50.42B
Total Liabilities & Equity $93.03B $91.68B $89.98B
SUPPLEMENTAL
Shares Outstanding 1.28B 1.28B 1.31B
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $7.33B $7.04B $6.79B
Capital Expenditures $1.90B $1.86B $1.59B
Cash from Investing $-2.93B $-1.94B $-2.37B
Cash from Financing $-4.75B $-4.36B $-4.45B
Free Cash Flow $5.43B $5.19B $5.20B
Beginning Cash (CFS) $2.22B $1.28B $1.54B
Net Change in Cash $-355.00M $746.00M $-29.00M
Effect of FX on Cash $85.00M $188.00M $-230.00M
Calculated Ending Cash $1.95B $2.22B $1.28B
Cash per BS $1.95B $2.22B $1.28B
Cash scope difference (CFS − BS) - - -
Cash per CFS $1.95B $2.22B $1.28B

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is Medtronic plc's annual revenue?

Medtronic plc reported $37.54B in revenue for trailing twelve months (ending July 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is Medtronic plc profitable?

Yes. Medtronic plc reported $5.23B in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does Medtronic plc generate free cash flow?

Yes. Free cash flow was $6.13B for trailing twelve months. Operating cash flow was $8.04B.